Clinical data focus for the smallest players
Our final look at upcoming catalysts sees data expected from Replimune, TCR2 Therapeutics, Anavex and more.
Upcoming events – Kalvista aims for acuity and a me-too from Sanofi approaches
As Kalvista hopes to attract Merck & Co, Sanofi plays catch-up with Genmab.
Where now for Oxurion?
The failure of its lead product in diabetic macular oedema, a limited pipeline and limited cash leaves Oxurion with few options.
Upcoming events – key tests approach for Biogen and Kalvista
Biogen needs a win with its Tecfidera follow-on, while Kalvista hopes to make HAE where Biocryst failed.
